Voyager Therapeutics, Inc.
VYGR
$3.17
-$0.26-7.58%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -66.83% | -93.03% | 433.79% | 509.48% | -87.03% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -66.83% | -93.03% | 433.79% | 509.48% | -87.03% |
| Cost of Revenue | 16.37% | 27.38% | 16.93% | 56.71% | 45.91% |
| Gross Profit | -230.69% | -141.25% | 73.59% | 71.55% | -105.74% |
| SG&A Expenses | 12.00% | -12.19% | -1.09% | 22.39% | -4.66% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 15.31% | 16.12% | 12.57% | 47.31% | 29.36% |
| Operating Income | -114.38% | -165.71% | 53.30% | 40.91% | -113.17% |
| Income Before Tax | -173.81% | -159.25% | 65.48% | 54.32% | -109.07% |
| Income Tax Expenses | 164.29% | -28.95% | 124.29% | -59.32% | -98.01% |
| Earnings from Continuing Operations | -173.80% | -161.15% | 65.08% | 54.34% | -109.13% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -173.80% | -161.15% | 65.08% | 54.34% | -109.13% |
| EBIT | -114.38% | -165.71% | 53.30% | 40.91% | -113.17% |
| EBITDA | -124.72% | -162.30% | 55.72% | 43.99% | -112.09% |
| EPS Basic | -167.94% | -146.40% | 73.53% | 65.57% | -106.50% |
| Normalized Basic EPS | -168.09% | -141.28% | 73.84% | 65.58% | -106.45% |
| EPS Diluted | -165.80% | -147.68% | 72.90% | 64.73% | -106.80% |
| Normalized Diluted EPS | -168.09% | -142.30% | 73.84% | 65.58% | -106.69% |
| Average Basic Shares Outstanding | 2.16% | 31.81% | 31.89% | 32.63% | 40.57% |
| Average Diluted Shares Outstanding | 2.16% | 28.61% | 31.89% | 32.63% | 35.47% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |